Cue Biopharma, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
CUE$18.76-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Collaboration revenue | $5,686 | $421 |
| Operating expenses: | ||
| General and administrative | 4,152 | 4,173 |
| Research and development | 6,897 | 8,547 |
| (Gain) on lease termination | (10) | — |
| Total operating expenses | 11,039 | 12,720 |
| Loss from operations | (5,353) | (12,299) |
| Other income (expense): | ||
| Interest income | 179 | 170 |
| Interest expense | (4) | (128) |
| Total other income, net | 175 | 42 |
| Net loss | $(5,178) | $(12,257) |
| Net loss per common share – basic and diluted | $(1.08) | $(4.95) |
| Weighted average common shares outstanding – basic and diluted | 4,807,494 | 2,475,156 |
(*) The number of shares and per share amounts have been retroactively adjusted to reflect the one-for-thirty (1-for-30) reverse stock split, which was effective on April 23, 2026. See Note 2.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.